7-09-2025, 19:30

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Notified -
Globe Newswire7-09-2025, 19:30